Note: The video and audio linked above were generated with the assistance of AI. Clinical accuracy has been reviewed, but no AI-generated content can be guaranteed to be fully error-free.
Figure 1. Epidemiologic estimates in CAD depend on definition and data source. Strictly adjudicated cohorts yield lower incidence and prevalence than administrative datasets, reflecting differences in case definition, testing practices, and ascertainment. Demographic patterns, such as older age at presentation and mild female predominance, align with the biology of an indolent clonal B-cell disorder. Epidemiology therefore reflects methodology as much as disease.
Knowing the estimates is useful; understanding how they are generated is essential.
Figure 2. Why epidemiologic estimates differ in cold agglutinin disease. Incidence and prevalence vary depending on how cases are defined and how data are collected. Strictly adjudicated cohorts apply narrow diagnostic criteria and typically yield lower estimates, whereas administrative datasets use broader coding definitions and often produce higher values. The difference reflects methodology as much as disease.
Why CAD epidemiology is harder than it looks
Cold agglutinin disease (CAD) is rare, but estimating how rare depends heavily on definitions and methods. Many datasets cannot cleanly distinguish among several biologically and clinically distinct entities. Administrative datasets, meaning claims-based or registry datasets driven primarily by diagnostic codes rather than adjudicated clinical phenotyping, are especially prone to this problem.1
Primary chronic CAD vs secondary cold agglutinin syndrome (CAS) Primary CAD refers to a chronic clonal disorder characterized by cold agglutinin–mediated hemolysis, whereas secondary CAS occurs in association with infections or overt malignancy. Older literature and many administrative datasets collapse these entities.2 Clinically, this distinction matters because the epidemiologic profile of primary CAD, typically an indolent clonal disorder of older adults, does not apply to younger patients with infection-related cold agglutinin syndromes, whose evaluation and management follow different logic.
Transient cold agglutinins vs hemolytic disease Low-titer, low–thermal-amplitude cold agglutinins are common, particularly after respiratory infections, and often do not cause sustained hemolysis or anemia.3
True CAD vs mixed autoimmune hemolytic anemia (AIHA) Mixed AIHA, with coexistence of warm IgG and cold IgM autoantibodies, is pathobiologically distinct and is typically excluded from rigorously phenotyped CAD cohorts.4
These distinctions matter. Incidence and prevalence estimates vary substantially depending on case definition, testing thresholds, and data source. Administrative datasets in particular reflect diagnostic behavior as much as biology.5
This is not unique to CAD. It is a general rule of rare-disease epidemiology: the rarer the condition, the more estimates depend on how cases are defined and found. Unless otherwise specified, the estimates below refer to primary chronic CAD with sustained hemolysis and no overt secondary driver.
How common is CAD?
Tier 1 scaffold
CAD is uncommon and represents a minority subtype of autoimmune hemolytic anemia (AIHA).
Key quantitative orientation anchors useful for clinicians:6
CAD accounts for roughly 15%–25% of AIHA.
In classic population-based studies of primary chronic CAD, incidence is approximately 1 new case per million people per year.
Frequently cited Northern European estimates suggest prevalence around 15–20 per million, although reported ranges across regions and methods span roughly 5–20 per million, reflecting both geographic and methodological differences.
These figures come from cohorts with careful phenotyping and exclusion of secondary and mixed forms.
Tier 2 nuance
More recent claims-based analyses report higher estimates:7
Annual incidence on the order of several cases per million.
Prevalence estimates higher than classic cohort data depending on database and coding strategy.
These larger numbers likely reflect broader diagnostic coding, inclusion of mixed or secondary phenotypes, and older insured populations. They underscore how strongly epidemiologic estimates depend on method rather than biology alone.
Recent multi-database analyses from North America report incidence estimates on the order of 0.6–1.2 per 100,000 persons, illustrating how broader claims-based definitions produce substantially higher apparent disease frequency.
Most patients present after age 50, commonly in the seventh decade, with median age at diagnosis near the late 60s.9
Age-dependent increases in incidence are particularly evident in population datasets.10
This age distribution is biologically coherent. CAD is usually driven by an indolent clonal B-cell population, and such clones accumulate over time, making late presentation expected rather than incidental.
Sex
A mild female predominance is consistently reported:11
large cohorts show male-to-female ratios near 0.5–0.6.
This pattern is reproduced in both clinically adjudicated cohorts and administrative data. However, the biological basis for sex distribution in CAD is not well established and may differ from mechanisms proposed for other autoimmune conditions, despite the superficial parallel.
Geography and climate
Temperature exposure is central to symptom expression in CAD, but its relationship to disease occurrence is less clear.
European population-based studies report higher incidence and prevalence in colder regions compared with warmer ones; for example, multinational cohort data show incidence near 1.9 per million per year in Norway versus about 0.5 per million in Italy, with prevalence roughly 20 versus 5 per million.12
In contrast, contemporary datasets do not always demonstrate a consistent geographic gradient despite substantial climatic variation.
This apparent paradox suggests that climate may influence clinical expression and detection more than true disease incidence. Differences in ascertainment, referral patterns, and diagnostic thresholds likely contribute.
Secondary cold agglutinin syndromes and triggers
Cold antibody–mediated hemolysis also occurs secondary to other conditions, including:13
infections, classically Mycoplasma pneumoniae and Epstein–Barr virus
lymphoproliferative disorders, often indolent B-cell processes
The epidemiology of secondary CAS is difficult to quantify. Many cases are transient, under-tested, or inconsistently coded, and most datasets do not reliably separate primary CAD from secondary or mixed forms. Even contemporary epidemiologic datasets that attempt to exclude obvious secondary drivers likely retain substantial residual misclassification.
For clinicians, this uncertainty matters directly: when cold agglutinin–mediated hemolysis is encountered, epidemiologic literature cannot reliably predict how often the presentation represents primary versus secondary disease. Diagnostic evaluation therefore cannot rely on prevalence assumptions alone.
Burden at the population level
Although rare, CAD is not trivial at the population level.
Cohort and registry studies highlight meaningful morbidity.14
Contemporary analyses report signals of increased thromboembolic risk and excess mortality in some populations, possibly reflecting complement activation and hemolysis-associated prothrombotic pathways.15
Interpretation of these findings depends heavily on case definition, comparator selection, and disease duration, and they are explored in greater depth in the Natural History and Prognosis spokes.
Importantly, symptom burden and quality-of-life impairment often exceed what clinicians would predict from hemoglobin level alone.16 This discordance reflects disease features not captured by hemoglobin, including cold-induced circulatory symptoms, fatigue disproportionate to anemia severity, behavioral cold avoidance, and cumulative psychosocial burden. Numbers measure one dimension of disease; patients live the whole system.
Key Points
epidemiologic estimates depend on case definition and data source
administrative datasets often yield higher rates than adjudicated cohorts
Key statements in this spoke are grounded in the following evidence:
CAD accounts for approximately 15–25% of AIHA
incidence in classic cohorts ≈ 0.5–1.9 per million/year
prevalence ≈ 5–20 per million in Northern Europe
median age at diagnosis ≈ late 60s
mild female predominance (M:F ~0.5–0.6)
The ranges above reflect the full spread across published studies, whereas single figures cited in the text represent central estimates from rigorously phenotyped cohorts.
Sources supporting these statements: Berentsen S et al. Cold agglutinin disease revisited. Blood. 2020; Blood. 2020;136:480; Blood Adv. 2019;3:2980; Gertz MA. Cold autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2022.
